Heart failure-a historical perspective

Pediatric Heart Failure

Volumn , Issue , 2005, Pages 1-29

  Rudolph, Abraham M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953660443     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (91)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns and opportunities. N Engl J Med 1997; 337:1360-1369.
2. Redfield MM. Heart failure-an epidemic of uncertain proportions. N Engl J Med 2002; 347:1442-1444.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999; 159:29-34.
4. MacKenzie J. Diseases of the Heart. London: Oxford Medical Publications, 1913.
5. Lewis T. Diseases of the Heart Described for Practitioners and Students. 2nd ed. New York: MacMillan Co., 1937.
6. Francis GS, Gessler JP, Sonnenblick EH. In: Funster V, Alexander RW, O’Rourke RA, Wellens HJ, eds. Hurst’s the Heart. 10th ed. New York: McGraw-Hill, 2000.
7. LeJemtel TH, Sonnenblick EH, Frishman WH. Diagnosis and management of heart failure. In: O’Rourke RA, Funster V, Alexander RW, Roberts R, King SB III, Wellens HJJ, eds. Hurst’s the Heart- Manual of Cardiology. New York: McGraw-Hill, 2001.
8. Braunwald E. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s Principle of Internal Medicine. New York: McGraw-Hill, 2001.
9. Barger AC, Ross RS, Price HL. Reduced sodium excretion in dogs with mild valvular lesions of the heart, and in dogs with congestive failure. Am J Physiol 1955; 180:249.
10. Barger AC, Yates FE, Rudolph AM. Renal hemodynamics and sodium excretion in dogs with graded valvular damage, and in congestive failure. Am J Physiol 1961; 200:601-608.
11. Farber SJ, Soberman RJ. Total body water and total exchangeable sodium in edematous states due to cardiac, renal or hepatic disease. Clin Invest 1956; 35:779.
12. Holt LE. The Diseases of Infancy and Childhood. New York: Appleton and Co, 1897.
13. Abbott ME. Atlas of Congenital Cardiac Disease. New York: The American Heart Association, 1936.
14. Nadas AS. Pediatric Cardiology. Philadelphia: WB Saunders Co., 1957.
15. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018.
16. Rudolph AM. Congenital Diseases of the Heart. 2nd ed. Armonk: Futura Publishing, 2001.
17. Frank O. Zur Dynamik des Herzmuskels. Z Biol 1895; 27:370-447.
18. Starling EH. The Lineacre Lecture on the Law of the Heart. Delivered at Cambridge. London: Longmans, Green, 1918.
19. Sarnoff SJ, Berglund E. Ventricular function: I. Starling’s law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation 1954; 9:706.
20. Sarnoff SJ, Brockman SK, Giimore JP, Linden RJ, Mitchell JH. Regulation of ventricular contraction: influence of cardiac sympathetic and vagal nerve stimulation on atrial and ventricular dynamics. Circ Res 1960; 8:1108.
21. Ross J Jr. Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function. Prog Cardiovasc Dis 1976; 18:255-264.
22. Friedman WF. The intrinsic properties of the developing heart. In: Sonnenblick E, Leschi M, Friedman WF, eds. Neonatal Heart Disease. New York: Grune and Stratton, 1973:21-50.
23. Klopfenstein HS, Rudolph AM. Postnatal changes in the circulation and responses to volume loading in sheep. Circ Res 1978; 42:839-845.
24. Teitel DF, Iwamoto HS, Rudolph AM. Effects of birth-related events on central blood flow patterns. Pediatr Res 1987; 22:557-566.
25. Hawkins J, Van Hare GF, Schmidt KG, Rudolph AM. Effects of increasing afterload on left ventricular output in fetal lambs. Circ Res 1989; 65:127-134.
26. Van Hare GF, Hawkins JA, Schmidt KG, Rudolph AM. The effects of increasing mean arterial pressure on left ventricular output in newborn lambs. Circ Res 1990; 67:78-83.
27. Lister G, Walter TK, Versmold HT, Dallman PR, Rudolph AM. Oxygen delivery in lambs: cardiovascular and hematologic development. Am J Physiol 1979; 237:H668-H675.
28. Fisher DJ, Rudolph AM, Heymann MA. Myocardial oxygen and carbohydrate consumption in fetal lambs in utero and in adult sheep. Am J Physiol 1980; 238:H399-H405.
29. Shelley HJ. Glycogen reserves and their changes at birth. Brit M Bull 1961; 17:137-143.
30. Starling EH. Points on pathology of heart disease. Lancet 1897; 1: 569-572.
31. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962; 267:650-654.
32. Lees MH, Bristow JD, Griswold HE, et al. Relative hypermetabolism in infants with congenital heart disease and undernutrition. Pediatrics 1965; 36:183.
33. Lees MH. Catecholamine metabolite excretion of infants with heart failure. J Pediatr 1966; 69:259-265.
34. Ross RD, Daniels SR, Schwartz DC, Harrison DW, Skulka R, Kaplan S. Plasma norepinephrine levels in infants and children with congestive heart failure. Am J Cardiol 1987; 59:911-914.
35. Rundqvist B, Elam M, Bergmann-Sverrisodottir Y, et al. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997; 95:169-175.
36. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73:615-621.
37. Shinebourne EA, Vapaavuori EK, Williams RL, Heymann MA, Rudolph AM. Development of baroreflex activity in unanesthetized fetal and neonatal lambs. Circ Res 1972; 31:710-718.
38. Lebowitz EA, Novick JS, Rudolph AM. Development of myocardial sympathetic innervation in the fetal lamb. Pediatr Res 1972; 6: 887-893.
39. Lipp JM, Rudolph AM. Sympathetic nerve development in the rat and guinea pig heart. Biol Neonate 1972; 21:76-82.
40. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Eng J Med 1982; 307:205-211.
41. Foody MA, Farrell MH, Krumholz HM. Bete-blocker therapy in heart failure: scientific review. JAMA 2002; 287:883-889.
42. Buchhorn R, Hulpke-Wette M, Ruschewski W, Ross RD, Fielitz J, Pregla R, Hetzer R, Regitz-Zagrosek V. Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease. Cardiol Young 2003; 13:36-43.
43. Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002; 40:2034-2038.
44. Birk E, Tyndall MR, Erickson LC, Rudolph AM, Roberts JM. Effects of thyroid hormone on myocardial adrenergic preceptor responsiveness and function during late gestation. Pediatr Res 1992; 31:468-173.
45. Roigas J, Roigas C, Heydeck D, Papies B. Prenatal hypoxia alters the postnatal development of beta-adrenoceptors in the rat myocardium. Biol Neonate 1996; 69:383-388.
46. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341:1276-1283.
47. Dorn GW II. Adrenergic pathways and left ventricular remodeling. Card Fail 2002; 8(6 suppl):S370-S373.
48. Brown JJ, Davies DL, Johnson VW, Lever AF, Robertson JL. Renin relationships in congestive heart failure, treated and untreated. Am Heart J 1970; 80:329-342.
49. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aidosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645-651.
50. Baylen BG, Johnson G, Tsang R, Srivastava L, Kaplan S. The occurrence of hyperaldosteronism in infants with congestive heart failure. Am J Cardiol 1980; 45:305-310.
51. The Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2:755-763.
52. The CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive failure: results of the cooperative North Scandinavian enalapril study group (CONSENSUS). N Eng J Med 1987; 316: 1429-1435.
53. Friedman WF, George BL. Medical progress-treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr 1985; 106:697-706.
54. Artman M, Graham TP. Guidelines for vasodilator therapy of congestive heart failure in infants and children. Am Heart J 1987; 113: 994-1005.
55. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram KR. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 1993; 88(suppl 1):107-124.
56. Yamazaki T, Shiojima I, Komuro I, Nagai R, Yazaki Y. Involvement of the renin-angiotensin system in the development of left ventricular hypertrophy and dysfunction. J Hypertens (suppl) 1984: 12: S153-S157.
57. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849-1865.
58. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996; 28:269-275.
59. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002; 27:92-98.
60. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71:12A-16A.
61. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341:709-717.
62. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1323.
63. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1:1385-1390.
64. Stewart JM, Zeballos GA, Woolf PK, Dweck HS, Gewitz MH. Variable arginine vasopressin levels in neonatal congestive heart failure. J Am Coll Cardiol 1988; 11:645-650.
65. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C. Vasopressin v2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107:2690-2696.
66. Stoupakis G, Klapholz M. Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. Heart Dis 2003; 5:215-223.
67. Kikuchi K, Nishioka K, Ueda T, Shiomi M, Takahashi Y, Sugawara A, Nakao K, Imura H, Mori C, Mikawa H. Relationship between plasma atrial natriuretic polypeptide concentration and hemodynamic measurements in children with congenital heart diseases. J Pediatr 1987; 111:335-342.
68. Vichiendilokkul A, Tran A, Racine E. Nesiritide: a novel approach for acute heart failure. Ann Pharmacother 2003; 37:247-258.
69. Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure. Drugs 2003; 63:47-70.
70. Withering W. An Account of the Foxglove, and Some of Its Medical Uses: With Practical Remarks on Dropsy and Other Diseases. London: G.G.J. and J. Robinson, 1785.
71. Fothergill JM. Digitalis: Its Mode of Action. London, 1871.
72. +, and ATPase in the inotropic action of digitalis. Pharmacol Rev 1977; 29:187-220.
73. Rudolph AM, Rokaw SN, Barger AC. Chronic catheterization of the renal artery: technic for studying direct effects of substances on kidney function. Proc Soc Exp Biol Med 1956; 93:323-326.
74. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989; 80:65-77.
75. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensinconverting-enzyme inhibitors: radiance study. N Engl J Med 1993; 329:1-7.
76. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the proved trial. Proved investigative group. J Am Coll Cardiol 1993; 22:955-962.
77. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533.
78. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995; 92:1801-1807.
79. Slatton ML, Irani WN, Hall SA, Marcoux LG, Page RL, Grayburn PA, Eichhorn EJ. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?J Am Coll Cardiol 1997; 29: 1206-1213
80. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871-878.
81. McCullough H, Rupe WA. Studies of dosage of digitalis in children. South Med J 1922; 15:381-385.
82. Nadas AS, Rudolph AM, Reinhold JDL. The use of digitalis in infants and children. New Engl J Med 1953; 248:98-105.
83. Berman W Jr, Ravenscroft PJ, Sheiner LB, Heymann MA, Melmon KL, Rudolph AM. Differential effects of digoxin at comparable concentrations in tissues of fetal and adult sheep. Circ Res 1977; 41:635-642.
84. Levine OR, Blumenthal S. Digoxin dosage in premature infants. Pediatrics 1962; 29:18.
85. Berman W Jr, Yabek SM, Dillon T, Niland C, Corlew S, Christensen D. Effects of digoxin in infants with congested circulatory state due to a ventricular septal defect. N Engl J Med 1983; 308:363-366.
86. Kimball TR, Daniels SR, Meyer RA, Hannon DW, Tian J, Shukla R, Schwartz DC. Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am J Cardiol 1991; 68:1377-1382.
87. Oparil S, Bishop SP, Ciubb FJ Jr. Myocardial cell hypertrophy or hyperplasia. Hypertension 1984; (suppl III):III38-III43.
88. Rudolph AM. Myocardial growth before and after birth: clinical implications. Acta Paediatr 2000; 89:1-5.
89. Segar JL, Scholz TD, Bedell KA, Smith OM, Huss DJ, Guillery EN. Angiotensin AT1 receptor blockade fails to attenuate pressure-overload cardiac hypertrophy in fetal sheep. Am J Physiol 1997; 273: R1501-R1508.
90. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science 2002; 298:2188-2141.
91. Sachinidis A, Kolossov E, Fleischmann BK, Hescheler J. Generation of cardiomyocytes forms embryonic stem cells. Herz 2002; 27:589-597.